141 related articles for article (PubMed ID: 32377702)
1. Juglone potentiates BRAF inhibitor‑induced apoptosis in melanoma through reactive oxygen species and the p38‑p53 pathway.
Li Z; Liu X; Li M; Chai J; He S; Wu J; Xu J
Mol Med Rep; 2020 Jul; 22(1):566-574. PubMed ID: 32377702
[TBL] [Abstract][Full Text] [Related]
2. Juglone potentiates TRAIL‑induced apoptosis in human melanoma cells via activating the ROS‑p38‑p53 pathway.
Liu X; Chen Y; Zhang Y; Du J; Lv Y; Mo S; Liu Y; Ding F; Wu J; Li J
Mol Med Rep; 2017 Dec; 16(6):9645-9651. PubMed ID: 29039537
[TBL] [Abstract][Full Text] [Related]
3. Icariside II overcomes BRAF inhibitor resistance in melanoma by inducing ROS production and inhibiting MITF.
Liu X; Li Z; Li M; Chai J; He S; Wu J; Xu J
Oncol Rep; 2020 Jul; 44(1):360-370. PubMed ID: 32319656
[TBL] [Abstract][Full Text] [Related]
4. Critical role of reactive oxygen species (ROS) for synergistic enhancement of apoptosis by vemurafenib and the potassium channel inhibitor TRAM-34 in melanoma cells.
Bauer D; Werth F; Nguyen HA; Kiecker F; Eberle J
Cell Death Dis; 2017 Feb; 8(2):e2594. PubMed ID: 28151482
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.
Tap WD; Gong KW; Dering J; Tseng Y; Ginther C; Pauletti G; Glaspy JA; Essner R; Bollag G; Hirth P; Zhang C; Slamon DJ
Neoplasia; 2010 Aug; 12(8):637-49. PubMed ID: 20689758
[TBL] [Abstract][Full Text] [Related]
6. Potent Imidazothiazole-based Inhibitor of BRAF V600E Overcomes Acquired Resistance
Poudel M; Kim G; Bhattarai PY; Shin S; Zaraei SO; Oh CH; Choi HS
Anticancer Res; 2022 Jun; 42(6):2911-2921. PubMed ID: 35641256
[TBL] [Abstract][Full Text] [Related]
7. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
8. The MEK1/2 inhibitor AS703026 circumvents resistance to the BRAF inhibitor PLX4032 in human malignant melanoma cells.
Park SJ; Hong SW; Moon JH; Jin DH; Kim JS; Lee CK; Kim KP; Hong YS; Choi EK; Lee JS; Lee JL; Kim TW
Am J Med Sci; 2013 Dec; 346(6):494-8. PubMed ID: 24051957
[TBL] [Abstract][Full Text] [Related]
9. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF
Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK
Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467
[TBL] [Abstract][Full Text] [Related]
11. HI-511 overcomes melanoma drug resistance
Chang X; Zhang T; Wang Q; Rathore MG; Reddy K; Chen H; Shin SH; Ma WY; Bode AM; Dong Z
Theranostics; 2020; 10(21):9721-9740. PubMed ID: 32863956
[No Abstract] [Full Text] [Related]
12. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
13. METTL3 induces PLX4032 resistance in melanoma by promoting m
Bhattarai PY; Kim G; Poudel M; Lim SC; Choi HS
Cancer Lett; 2021 Dec; 522():44-56. PubMed ID: 34530048
[TBL] [Abstract][Full Text] [Related]
14. Involvement of superoxide and nitric oxide in BRAF(V600E) inhibitor PLX4032-induced growth inhibition of melanoma cells.
Yu L; Gao LX; Ma XQ; Hu FX; Li CM; Lu Z
Integr Biol (Camb); 2014 Dec; 6(12):1211-7. PubMed ID: 25363644
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
[TBL] [Abstract][Full Text] [Related]
16. Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors.
Choi J; Landrette SF; Wang T; Evans P; Bacchiocchi A; Bjornson R; Cheng E; Stiegler AL; Gathiaka S; Acevedo O; Boggon TJ; Krauthammer M; Halaban R; Xu T
Pigment Cell Melanoma Res; 2014 Mar; 27(2):253-62. PubMed ID: 24283590
[TBL] [Abstract][Full Text] [Related]
17. 17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.
Joshi SS; Jiang S; Unni E; Goding SR; Fan T; Antony PA; Hornyak TJ
PLoS One; 2018; 13(2):e0191264. PubMed ID: 29481571
[TBL] [Abstract][Full Text] [Related]
18. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G
Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714
[TBL] [Abstract][Full Text] [Related]
19. Juglone induces apoptosis of tumor stem-like cells through ROS-p38 pathway in glioblastoma.
Wu J; Zhang H; Xu Y; Zhang J; Zhu W; Zhang Y; Chen L; Hua W; Mao Y
BMC Neurol; 2017 Apr; 17(1):70. PubMed ID: 28388894
[TBL] [Abstract][Full Text] [Related]
20. BIK is involved in BRAF/MEK inhibitor induced apoptosis in melanoma cell lines.
Borst A; Haferkamp S; Grimm J; Rösch M; Zhu G; Guo S; Li C; Gao T; Meierjohann S; Schrama D; Houben R
Cancer Lett; 2017 Sep; 404():70-78. PubMed ID: 28720543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
